Cementos Bio Bio S.A. (SNSE:CEMENTOS)
Chile
· Delayed Price · Currency is CLP 1,730.00
0.00 (0.00%)
At close: Apr 27, 2026
Cementos Bio Bio Income Statement
Financials in millions CLP. Fiscal year is January - December.
Millions CLP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 370,540 | 359,565 | 349,104 | 334,004 | 289,468 | Upgrade
|
| Revenue Growth (YoY) | 3.05% | 3.00% | 4.52% | 15.38% | 19.33% | Upgrade
|
| Cost of Revenue | 227,354 | 222,102 | 219,413 | 228,479 | 186,287 | Upgrade
|
| Gross Profit | 143,187 | 137,462 | 129,692 | 105,525 | 103,181 | Upgrade
|
| Selling, General & Admin | 98,716 | 97,800 | 94,685 | 94,110 | 86,095 | Upgrade
|
| Other Operating Expenses | -563.18 | 445.7 | 120.09 | - | - | Upgrade
|
| Operating Expenses | 98,153 | 98,245 | 94,805 | 94,110 | 86,095 | Upgrade
|
| Operating Income | 45,034 | 39,217 | 34,887 | 11,415 | 17,086 | Upgrade
|
| Interest Expense | -8,981 | -10,708 | -14,353 | -11,141 | -3,561 | Upgrade
|
| Interest & Investment Income | 1,763 | 1,490 | 1,210 | 1,063 | 598.99 | Upgrade
|
| Currency Exchange Gain (Loss) | 385.21 | 3,877 | 434.34 | -1,311 | 1,425 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,136 | 1,260 | 3,574 | 1,954 | 2,114 | Upgrade
|
| EBT Excluding Unusual Items | 39,337 | 35,136 | 25,752 | 1,980 | 17,662 | Upgrade
|
| Gain (Loss) on Sale of Assets | 217.71 | 5,265 | 556.51 | 3,427 | 8,655 | Upgrade
|
| Asset Writedown | -287.57 | -508.61 | -584.07 | -2,550 | -988.27 | Upgrade
|
| Other Unusual Items | - | - | - | - | 685.41 | Upgrade
|
| Pretax Income | 39,671 | 40,970 | 26,622 | 5,635 | 33,911 | Upgrade
|
| Income Tax Expense | 6,576 | 8,571 | 3,812 | -4,926 | 6,885 | Upgrade
|
| Earnings From Continuing Operations | 33,095 | 32,399 | 22,809 | 10,561 | 27,026 | Upgrade
|
| Minority Interest in Earnings | -7.17 | 28.34 | -12.25 | -1.13 | -146.9 | Upgrade
|
| Net Income | 33,088 | 32,427 | 22,797 | 10,560 | 26,879 | Upgrade
|
| Net Income to Common | 33,088 | 32,427 | 22,797 | 10,560 | 26,879 | Upgrade
|
| Net Income Growth | 2.04% | 42.24% | 115.88% | -60.71% | 95.30% | Upgrade
|
| Shares Outstanding (Basic) | 264 | 264 | 264 | 264 | 264 | Upgrade
|
| Shares Outstanding (Diluted) | 264 | 264 | 264 | 264 | 264 | Upgrade
|
| EPS (Basic) | 125.23 | 122.73 | 86.28 | 39.97 | 101.73 | Upgrade
|
| EPS (Diluted) | 125.23 | 122.73 | 86.28 | 39.97 | 101.73 | Upgrade
|
| EPS Growth | 2.04% | 42.24% | 115.88% | -60.71% | 95.30% | Upgrade
|
| Free Cash Flow | 46,673 | 54,336 | 24,086 | 9,374 | 3,860 | Upgrade
|
| Free Cash Flow Per Share | 176.64 | 205.65 | 91.16 | 35.48 | 14.61 | Upgrade
|
| Dividend Per Share | - | 80.000 | 36.000 | 12.000 | 48.000 | Upgrade
|
| Dividend Growth | - | 122.22% | 200.00% | -75.00% | 14.29% | Upgrade
|
| Gross Margin | 38.64% | 38.23% | 37.15% | 31.59% | 35.64% | Upgrade
|
| Operating Margin | 12.15% | 10.91% | 9.99% | 3.42% | 5.90% | Upgrade
|
| Profit Margin | 8.93% | 9.02% | 6.53% | 3.16% | 9.29% | Upgrade
|
| Free Cash Flow Margin | 12.60% | 15.11% | 6.90% | 2.81% | 1.33% | Upgrade
|
| EBITDA | 59,900 | 53,550 | 48,082 | 24,159 | 30,270 | Upgrade
|
| EBITDA Margin | 16.17% | 14.89% | 13.77% | 7.23% | 10.46% | Upgrade
|
| D&A For EBITDA | 14,866 | 14,332 | 13,195 | 12,744 | 13,184 | Upgrade
|
| EBIT | 45,034 | 39,217 | 34,887 | 11,415 | 17,086 | Upgrade
|
| EBIT Margin | 12.15% | 10.91% | 9.99% | 3.42% | 5.90% | Upgrade
|
| Effective Tax Rate | 16.58% | 20.92% | 14.32% | - | 20.30% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.